Browsing Tag
elraglusib
2 posts
Is elraglusib emerging as a new frontline option in metastatic PDAC?
Read how Actuate Therapeutics’ elraglusib Phase 2 survival data could reshape metastatic PDAC treatment and investor expectations.
April 16, 2026
How elraglusib’s long-term Phase 2 survival data positions Actuate Therapeutics in a difficult pancreatic cancer market
Find out how elraglusib’s long-term Phase 2 survival data is positioning Actuate Therapeutics in the challenging metastatic pancreatic cancer market.
January 15, 2026